Pravastatin vs Usual Care in Hypertensive Patients With Moderate Hypercholesterolemia (ALLHAT-LLT)

This is the cholesterol arm of the giant ALLHAT trial, and it is the rare statin study that came up empty — a result worth understanding precisely because it seems to contradict the others.

Older hypertensive patients with moderately high LDL were randomized to pravastatin or “usual care.” Pravastatin lowered LDL more than usual care, but produced no significant reduction in death or coronary events. On its face, a statin that did not work.

The explanation lies in the design rather than the drug. This was an open-label trial comparing against usual care, not placebo — and over time, many patients in the usual-care group were started on statins by their own doctors. The LDL gap between the two arms narrowed to a modest 17 percent. With the groups converging, the trial had little contrast left to detect a benefit. Read alongside the placebo-controlled statin trials and the large meta-analyses, ALLHAT-LLT is best understood as a study diluted by real-world drift, not as evidence that statins fail.

We rate the evidence moderate. It is a large trial, but its open-label design and contaminated comparison limit what its null result can tell us — a useful lesson in why trial architecture matters as much as size.